Can Psilocybin Help With Anxiety?

Exploring the emerging clinical evidence behind psilocybin as a potential treatment for anxiety disorders.

Science & Education  |  ShroomTown  |  October 2023

In recent years, interest in the therapeutic potential of psilocybin, the psychoactive compound in magic mushrooms, has significantly increased. While psilocybin is often associated with altered states of consciousness, a growing body of clinical research suggests it may also offer meaningful relief for individuals suffering from anxiety disorders. This article looks at the actual studies behind that claim, how the compound appears to work in the brain, and what the real limitations of the current research are.

Understanding Anxiety

Anxiety is one of the most prevalent mental health challenges today, affecting millions of individuals globally. While conventional treatments, such as cognitive-behavioral therapy (CBT) and prescription medications like SSRIs, can be effective, a significant portion of people continue to experience persistent symptoms despite ongoing care. This treatment-resistant gap is a major part of why researchers have turned to psilocybin as an alternative avenue worth studying seriously.

What the Research Actually Shows

The most frequently cited studies in this space come from Johns Hopkins and NYU, both of which ran trials on psilocybin-assisted therapy for anxiety and depression related to life-threatening cancer diagnoses. Published in the Journal of Psychopharmacology in 2016, these trials found that a single high-dose psilocybin session, paired with psychological support, produced substantial and sustained reductions in anxiety and depressive symptoms for many participants, with effects that in some cases persisted for six months or longer after just one or two sessions.

Imperial College London’s Centre for Psychedelic Research has since extended this work into generalized anxiety and treatment-resistant depression more broadly, using brain imaging to study what’s actually happening during and after a session. Their findings, along with follow-up trials at institutions including NYU and UCSF, have been consistent enough that psilocybin-assisted therapy is now being studied through formal regulatory pathways in multiple countries, though it remains investigational and is not an approved treatment in Canada outside of specific clinical or exemption contexts.

How Psilocybin Works in the Brain

Psilocybin itself isn’t active until the body converts it to psilocin, which binds primarily to the 5-HT2A serotonin receptor, a receptor heavily involved in mood regulation, cognition, and perception. This binding is thought to temporarily reduce activity in the default mode network, the brain circuit associated with self-referential thought and rumination, the same looping, self-critical thinking pattern that characterizes a lot of chronic anxiety.

Researchers have also observed that psilocybin appears to increase neuroplasticity, the brain’s capacity to form new neural connections, at least in the days following a session. The working theory is that this temporary window of increased flexibility is what allows some people to step outside entrenched anxious thought patterns long enough to genuinely shift them, rather than just numbing the symptom.

Microdosing and Anxiety: A Different Picture

Most of the clinical research above involves a single high, therapeutic dose administered in a controlled clinical setting with trained support, not the kind of sub-perceptual microdosing many people practice independently. Microdosing research is younger and more mixed: some observational studies report reduced anxiety and improved emotional regulation among regular microdosers, but placebo-controlled trials have found smaller effects than self-reported surveys suggest, meaning expectation likely plays some role. If you’re specifically interested in what the microdosing literature says, our dedicated guide on microdosing for anxiety goes deeper into those findings.

Risks, Cautions, and Responsible Use

While the therapeutic promise of psilocybin is significant, it’s equally important to acknowledge the risks and limitations. Key considerations include:

• Set and Setting: The clinical trials showing the strongest results paired psilocybin with a controlled environment and trained psychological support, not a solo experience with no preparation. Environment and mindset significantly influence outcomes.
• Medication Interactions: SSRIs and SNRIs can blunt psilocybin’s effects due to receptor overlap, while MAOIs can dangerously intensify them. Lithium in particular carries a documented risk of seizures when combined with psychedelics.
• Medical History: Individuals with a personal or family history of psychosis, schizophrenia, or bipolar disorder are at meaningfully higher risk of adverse psychiatric reactions and should not use psilocybin without medical guidance.
• Anxiety Can Temporarily Increase First: It’s common for anxiety to spike during the come-up of a session before any benefit appears. This is a normal part of the arc for many people, not necessarily a sign something is wrong, but it’s worth knowing in advance so it doesn’t feel alarming in the moment.

Conclusion

The clinical evidence for psilocybin’s role in anxiety treatment is genuinely stronger than it was even a few years ago, backed by real trials at respected institutions with measurable, sustained outcomes for many participants. But it’s still early, investigational, and most robust in a supervised setting with a meaningful dose, not casual independent use. For anyone considering psilocybin specifically to work with anxiety, that gap between the clinical evidence and how most people actually access the substance is worth sitting with honestly before starting.